Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,381 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,381 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total value of $224,064.84. Following the completion of the transaction, the director now owns 319,752 shares of the company’s stock, valued at $13,314,473.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pro-Dex Trading Up 1.3 %

Shares of PDEX stock traded up $0.52 on Tuesday, reaching $41.79. 20,432 shares of the company’s stock were exchanged, compared to its average volume of 27,696. The company’s fifty day simple moving average is $47.75 and its 200 day simple moving average is $34.11. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $136.24 million, a PE ratio of 27.14 and a beta of 0.56.

Wall Street Analyst Weigh In

PDEX has been the topic of a number of research reports. Ascendiant Capital Markets lifted their price objective on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

Institutional Trading of Pro-Dex

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares during the period. Renaissance Technologies LLC boosted its position in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares in the last quarter. FMR LLC increased its holdings in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after acquiring an additional 1,028 shares during the period. Bard Associates Inc. raised its position in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after acquiring an additional 2,031 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares in the last quarter. 15.28% of the stock is currently owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.